Study design
cardiac or cerebrovascular event, AF/AT, atrial flutter
ATRIAL FIBRILLATION, ATRIAL FLUTTER, ATRIAL TACHYCARDIA
This is a prospective, double-blind, randomized, placebo-controlled trial. The manufacturer of dapagliflozin did not provide any financial support or take part in the design of the study. This study is investigator initiated, and the study protocol was in accordance with the Declaration of Helsinki and approved by the ethics committee of Beijing Anzhen Hospital (No. KS2023017). The study was registered at Flowchart of the study. AF, atrial fibrillation; AF/AT, atrial flutter or atrial tachycardia; CMIV, Cox-Maze IV; MACCE, major cardiac or cerebrovascular event.